Navigation Links
Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
Date:6/29/2011

PRINCETON, N.J., June 29, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Joel Posener, MD, has joined the Company as Executive Medical Director, Neuroscience. Dr. Posener will support PharmaNet project teams conducting clinical trials in psychiatry and neurology, and will provide drug development advice to clients in the area of neuroscience.

"We are thrilled Joel has joined PharmaNet," said Steven Leventer, PhD, Vice President and General Manager, Neuroscience. "His distinguished medical and clinical credentials will be a valuable addition to PharmaNet's experienced neuroscience team. Joel's appointment further demonstrates our commitment to help our clients develop innovative neuroscience therapeutics."

Dr. Posener obtained his medical degree from McGill University, completed a residency in psychiatry and fellowship in psychiatric research at Harvard Medical School and Massachusetts Mental Health Center, and is board certified in Psychiatry. Prior to joining PharmaNet, Dr. Posener held roles at Wyeth as Senior Director, Neuroscience Medical Research and Senior Director, Early Development and Clinical Pharmacology. He directed Phase II projects in a variety of psychiatric indications including cognitive impairment in schizophrenia, bipolar disorder and depression. Dr. Posener has also managed early clinical development programs in schizophrenia, depression and Alzheimer's disease.

Before joining the pharmaceutical industry, Dr. Posener served on the faculty of Harvard Medical School and Washington University School of Medicine in St. Louis, where he was also Medical Director of Metropolitan St. Louis Psychiatric Center, an academically affiliated public psychiatric hospital. He has published
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Eduard Alberts, Ph.D. Joins Sanford Rose Associates - San Francisco
2. Amicus Therapeutics Joins Russell 3000® Index
3. Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
4. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
5. Matthias Spaenle, MD, Joins Oppenheimers Investment Banking Group as Managing Director - Healthcare
6. William T. Boehm Joins Neogens Board of Directors
7. Scott Garrett Joins Water Street Healthcare Partners
8. Sigma® Life Science Joins AMDeCs Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers
9. Ed Weimer Joins Delta Point, Inc. as Executive Account Director
10. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
11. Former Cerner Chief Operating Officer Joins Netsmart Technologies Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
(Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
(Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), a ... to personalize and advance the treatment and management of ... Lucier as chairman of Epic,s board of directors. ... Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board of ... rare cell analysis platform with special focus on the ...
(Date:7/30/2014)... 30, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that their third ... the reduction of recurrence of hypertrophic scars ... initiated. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... Informed Medical Communications (IMC), a leading provider ... today announced the appointment of Kerry Crawford to ... In this critical role, Kerry will lead operations ... client relationship management systems. This key addition ...
... Collexis Holdings Inc.,(OTC Bulletin Board: CLXS), a ... announced today the launch of the world,s first,CTSA ... 38 institutions and,their more than 60,000 life science ... are also winners of the Clinical Translational Science,Awards ...
... Denmark, March 3 Following the,completion of the Phase ... Nordic has held an end of Phase,II meeting with ... meeting was,a success and there was an open and ... This meeting represented the first ever formal discussions ...
Cached Biology Technology:Informed Medical Communications Appoints New Senior Manager, Strategic Operations 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 3Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3
(Date:7/30/2014)... of researchers from the University of Helsinki and the ... reproduce in mice morphological changes which have taken millions ... in the embryonic development of mice teeth, induced in ... very similar to those observed in the fossil registry ... years ago. , To modify the development of ...
(Date:7/30/2014)... of $1 million from the Cornelia Cogswell Rossi Foundation ... Center. , The newly established Connie Cogswell ... develop a greater breadth and depth of knowledge of ... pace of research to improve human health. , The ... the Laboratory and its external partners, supporting research to ...
(Date:7/30/2014)... , July 30, 2014 ... mitigation and liveness detection solutions for the biometric ... an industry consortium revolutionizing online authentication with standards ... Mark Cornett , "The decision to join FIDO ... biometric authentication pervasive in use. We believe the ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2NexID Biometrics Joins the FIDO Alliance 2
... of us never considered eating the mud pies we made ... dining on dirt is nothing out of the ordinary. Now ... The Quarterly Review of Biology helps explain why. ... human geophagythe eating of earthis that it protects the stomach ...
... a researcher, please contact the Communications and External Relations staff member ... ORNL and its research and development activities, please refer to one ... or comment, you can send it to news@ornl.gov . ... Unsafe commercial motor vehicles may be off the ...
... like a computer. An organism,s genome is the software ... do. But instead of electronic circuitry, life relies on ... organisms to function. Now, researchers at the California Institute ... circuit ever created from scratch, made with DNA-based devices ...
Cached Biology News:Eating dirt can be good for the belly, researchers find 2Eating dirt can be good for the belly, researchers find 3Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2011 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 3Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 4
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... MOISTURE. Protein synthesis inhibitor. Inhibits translation ... polypeptide chains. Induces DNA fragmentation in ... cells. Purity: ≥98% by TLC. ...
... Stabilizer is a bovine protein-free alternative ... is an aqueous solution that contains ... buffer (3-(N-Morpholino) propanesulfonic acid), pH 6.0 ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... quantitation kit is used to quantitate double-stranded DNA ... RNA or protein. With this kit, DNA is ... detected with a VersaFluor or other fluorometer. The ... ng per ml to 5 micrograms per ml ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
Biology Products: